Case overview
| Case | Age | Sex | IMDC | Subtype | NG | Sarcomatoid features | ICI | Prior Tx | Time to irAIN (months)* | Biopsy proven AIN? | Cr [mg/dL] (eGFR [mL/min/1.73 m2]) | irAIN Tx† | irAIN Tx duration (months) | BR | DOR (months) | ||
| Baseline | Peak | Recovery | |||||||||||||||
| 1 | 71 | M | Int. | ccRCC | 4 | 10% | N | Pazo | 12.8 | Yes | 1.3 (55) | 2.25 (35) | 1.48 (50) | None | N/A | CR | 52§¶ |
| 2 | 70 | M | Poor | ccRCC | 2** | Absent | N | Pazo PT2385 Axi | 10.8 | Yes | 1.5 (42) | 10 (5) | 1.85 (36) | Mpred 500 mg | 3 | PR‡ | 14 |
| 3 | 48 | M | Int. | ccRCC | 3** | Absent | N+I | None | 1.4 | No | 1.2 (>60) | 2.45 (28) | 1.28 (60) | Pred 1 mg/kg daily†† Myco 1.5 g BID | 4 | CR | 29¶ |
| 4 | 58 | M | Poor | pRCC | 3 | Absent | N+I | None | 2.1 | Yes | 0.8 (>60) | 2.65 (37) | 1.74 (49) | Pred 1 mg/kg daily | 3 | PR | 8 |
*From start of ICI therapy.
†Maximal immunosuppressive therapy, tapered over treatment duration.
‡Following pseudoprogression.
§At 36 months post-ICI initiation, patient developed an asymptomatic brain lesion which was irradiated.
¶Ongoing.
**Diagnosis via biopsy of primary tumor.
††Tapered over 7 weeks
Axi, axitinib; BID, twice daily; BR, best response; ccRCC, clear cell RCC; CR, complete response; DOR, duration of response; I, Ipilimumab; IMDC, international metastatic RCC database risk group score at the time of starting ICI; Int, intermediate risk; Mpred, methylprednisolone; Myco, mycophenolate; N, Nivolumab; NG, nuclear grade; Pazo, Pazopanib; PR, partial response; pRCC, papillary RCC; Pred, Prednisone; PT2385, experimental HIF-2α inhibitor; Tx, treatment.